Literature DB >> 11579968

Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titer.

S Kono1, H Miyajima, M Sugimoto, Y Suzuki, Y Takahashi, A Hishida.   

Abstract

Glutamic acid decarboxylase (GAD) is the main target of humoral autoimmunity in patients with insulin-dependent diabetes mellitus (IDDM) and stiff-person syndrome. We reviewed the case of a 46-year-old woman who had cerebellar ataxia before getting stiff-person syndrome and IDDM with high anti-GAD autoantibody titers. This was a rare case in which there were both the clinical symptoms of stiff-person syndrome and cerebellar ataxia. In western blot analysis her serum reacted with 65-kDa proteins from rat cerebellum, cerebral cortex, and spinal cord. Autoantibodies to GAD may cause functional impairment of gamma-aminobutyric acid (GABA) neurons in the spinal cord as well as in the cerebellum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579968     DOI: 10.2169/internalmedicine.40.968

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  13 in total

Review 1.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

Review 2.  Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review.

Authors:  José Fidel Baizabal-Carvallo; Marlene Alonso-Juarez
Journal:  J Neural Transm (Vienna)       Date:  2017-07-08       Impact factor: 3.575

Review 3.  Acquired ataxias: the clinical spectrum, diagnosis and management.

Authors:  Wolfgang Nachbauer; Andreas Eigentler; Sylvia Boesch
Journal:  J Neurol       Date:  2015-03-26       Impact factor: 4.849

Review 4.  Stiff person syndrome spectrum disorders; more than meets the eye.

Authors:  Scott D Newsome; Tory Johnson
Journal:  J Neuroimmunol       Date:  2022-06-12       Impact factor: 3.221

5.  GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies.

Authors:  Yasushi Hosoi; Makiko Suzuki-Sakao; Tatsuhiro Terada; Takashi Konishi; Yasuomi Ouchi; Hiroaki Miyajima; Satoshi Kono
Journal:  J Neurol       Date:  2013-10-05       Impact factor: 4.849

6.  Enhanced synaptic inhibition in the cerebellar cortex of the ataxic PMCA2(-/-) knockout mouse.

Authors:  Ruth M Empson; Helena Huang; Raghavendra Y Nagaraja; Chris J Roome; Thomas Knöpfel
Journal:  Cerebellum       Date:  2013-10       Impact factor: 3.847

7.  High titers of autoantibodies to glutamate decarboxylase in type 1 diabetes patients: epitope analysis and inhibition of enzyme activity.

Authors:  Christiane S Hampe; Murray E Maitland; Lisa K Gilliam; Thanh-H Thi Phan; Ian R Sweet; Jared R Radtke; Vasile Bota; Bruce R Ransom; Irl B Hirsch
Journal:  Endocr Pract       Date:  2013 Jul-Aug       Impact factor: 3.443

8.  Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia.

Authors:  Mario U Manto; Christiane S Hampe; Véronique Rogemond; Jérome Honnorat
Journal:  Orphanet J Rare Dis       Date:  2011-02-04       Impact factor: 4.123

Review 9.  'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

10.  Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with Stiff-Person Syndrome and other movement disorders.

Authors:  Clare N Lynex; Ian M Carr; Jack P Leek; Rajgopal Achuthan; Simon Mitchell; Eamonn R Maher; C Geoffrey Woods; David T Bonthon; Alex F Markham
Journal:  BMC Neurol       Date:  2004-11-30       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.